<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <STUDY accession="ERP131709" alias="KoroGenoEST3-Cov85" center_name="university of tartu, estonia">
    <IDENTIFIERS>
      <PRIMARY_ID>ERP131709</PRIMARY_ID>
      <EXTERNAL_ID namespace="BioProject">PRJEB47434</EXTERNAL_ID>
      <SUBMITTER_ID namespace="university of tartu, estonia">KoroGenoEST3-Cov85</SUBMITTER_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole genome sequencing of SARS-CoV-2 in Estonia</STUDY_TITLE>
      <STUDY_TYPE existing_study_type="Other"/>
      <STUDY_ABSTRACT>KoroGeno-EST-3 consortium's aim is to sequence SARS-CoV-2 from SARS-CoV-2 positive persons in Estonia during May to September 2021. The goal of this consortium is to generate genetical information (sequences) of SARS-CoV-2 which in combination with epidemiological and clinical data has the potential to inform interventions and policy decisions during the current COVID-19 epidemic in Estonia. The sequencing capacity will enable to monitor SARS-CoV-2 genetics in Estonia: (i) to determine variants of concern and variants of interest, their prevalence and the evolution of the virus; (ii) to determine the transmission networks; and (iii) to evaluate relationships between SARS-CoV-2 genetics and patients' clinical outcomes. In the future, this data could be linked with individuals' clinical data, COVID-19 outcomes, human genomics and metagenomics data, giving an opportunity to generate detailed insight into the COVID-19 disease.</STUDY_ABSTRACT>
      <STUDY_DESCRIPTION>KoroGeno-EST-3 consortium's aim is to sequence SARS-CoV-2 from SARS-CoV-2 positive persons in Estonia during May to September 2021. The goal of this consortium is to generate genetical information (sequences) of SARS-CoV-2 which in combination with epidemiological and clinical data has the potential to inform interventions and policy decisions during the current COVID-19 epidemic in Estonia. The sequencing capacity will enable to monitor SARS-CoV-2 genetics in Estonia: (i) to determine variants of concern and variants of interest, their prevalence and the evolution of the virus; (ii) to determine the transmission networks; and (iii) to evaluate relationships between SARS-CoV-2 genetics and patients' clinical outcomes. In the future, this data could be linked with individuals' clinical data, COVID-19 outcomes, human genomics and metagenomics data, giving an opportunity to generate detailed insight into the COVID-19 disease.</STUDY_DESCRIPTION>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>SUBMISSION_TOOL</TAG>
        <VALUE>ena-upload-cli v0.3.1 @ Galaxy</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>SUBMISSION_TOOL_VERSION</TAG>
        <VALUE>0.3.1</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>ENA-FIRST-PUBLIC</TAG>
        <VALUE>2021-09-09</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>ENA-LAST-UPDATE</TAG>
        <VALUE>2023-04-24</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
</STUDY_SET>
